See more : Etablissements Maurel & Prom S.A. (0F6L.L) Income Statement Analysis – Financial Results
Complete financial analysis of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Sichuan Expressway Company Limited (SEXHF) Income Statement Analysis – Financial Results
- ChannelAdvisor Corporation (ECOM) Income Statement Analysis – Financial Results
- Treace Medical Concepts, Inc. (TMCI) Income Statement Analysis – Financial Results
- Winstar Display Co., Ltd. (6916.TW) Income Statement Analysis – Financial Results
- DMG MORI AKTIENGESELLSCHAFT (GIL.DE) Income Statement Analysis – Financial Results
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS)
About Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. Its products include YISAIPU, a tumor necrosis factor inhibitor for rheumatism; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody injection; Cipterbin, an anti-HER2 monoclonal antibody. The company is also developing products for autoimmune diseases, tumors, and other diseases. The company was founded in 2002 and is based in Shanghai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.01B | 825.49M | 928.81M | 655.01M | 1.18B | 1.14B | 1.10B | 961.37M | 877.35M | 775.85M | 727.84M | 595.51M | 475.21M | 342.94M | 245.26M | 159.38M | 92.49M | 34.56M |
| Cost of Revenue | 223.04M | 201.20M | 210.02M | 102.29M | 145.97M | 118.28M | 104.72M | 68.02M | 56.15M | 54.38M | 40.17M | 39.37M | 38.40M | 28.64M | 23.15M | 15.33M | 17.45M | 10.83M |
| Gross Profit | 790.99M | 624.29M | 718.79M | 552.72M | 1.03B | 1.02B | 998.70M | 893.36M | 821.20M | 721.47M | 687.67M | 556.14M | 436.81M | 314.30M | 222.11M | 144.05M | 75.05M | 23.72M |
| Gross Profit Ratio | 78.00% | 75.63% | 77.39% | 84.38% | 87.60% | 89.64% | 90.51% | 92.93% | 93.60% | 92.99% | 94.48% | 93.39% | 91.92% | 91.65% | 90.56% | 90.38% | 81.14% | 68.65% |
| Research & Development | 282.30M | 313.28M | 455.09M | 340.25M | 278.89M | 198.71M | 122.26M | 175.61M | 177.77M | 124.44M | 74.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 16.17M | 21.99M | 33.27M | 27.75M | 145.08M | 28.59M | 28.66M | 88.53M | 112.07M | 98.13M | 77.84M | 110.80M | 97.30M | 73.06M | 58.80M | 50.28M | 35.94M | 47.99M |
| Selling & Marketing | 166.39M | 250.45M | 265.28M | 371.72M | 367.87M | 367.90M | 340.51M | 330.54M | 344.41M | 356.97M | 264.39M | 220.29M | 153.36M | 105.01M | 71.61M | 46.38M | 32.82M | 12.07M |
| SG&A | 182.17M | 272.43M | 298.55M | 399.46M | 512.94M | 396.49M | 369.18M | 419.06M | 456.47M | 455.10M | 342.23M | 331.09M | 250.66M | 178.07M | 130.42M | 96.66M | 68.76M | 60.05M |
| Other Expenses | 7.24M | 33.52M | 38.45M | 30.89M | 41.27M | -10.12M | -64.63M | 45.11M | 0.00 | 0.00 | 0.00 | 60.96M | 39.00M | 28.78M | 19.30M | 14.29M | 15.35M | 5.61M |
| Operating Expenses | 472.78M | 619.24M | 792.10M | 770.60M | 833.10M | 638.74M | 534.99M | 598.20M | 604.51M | 493.22M | 348.70M | 336.18M | 254.92M | 178.30M | 130.42M | 96.66M | 68.76M | 60.05M |
| Cost & Expenses | 695.82M | 820.44M | 1.00B | 872.89M | 979.07M | 757.02M | 639.72M | 666.22M | 660.66M | 547.59M | 388.86M | 375.55M | 293.32M | 206.95M | 153.56M | 111.99M | 86.21M | 70.89M |
| Interest Income | 39.64M | 20.00M | 23.94M | 14.62M | 30.77M | 33.10M | 27.14M | 12.39M | 20.27M | 17.54M | 8.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.59M | 1.32M | 171.96K | 122.17K | 95.79K | 1.60M | 4.07M | 152.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 96.08M | 122.41M | 135.46M | 136.02M | 132.17M | 120.14M | 84.84M | 76.15M | 66.91M | 56.82M | 51.31M | 41.95M | 36.12M | 30.60M | 28.56M | 26.06M | 25.21M | 44.15M |
| EBITDA | 424.71M | 168.17M | 62.15M | -97.33M | 356.83M | 531.47M | 517.51M | 381.11M | 431.64M | 323.19M | 396.75M | 261.91M | 218.00M | 166.59M | 120.26M | 73.44M | 29.97M | 7.82M |
| EBITDA Ratio | 41.88% | 15.42% | 5.62% | -14.86% | 25.79% | 44.10% | 52.20% | 39.64% | 49.20% | 41.66% | 54.51% | 44.09% | 46.03% | 48.73% | 48.89% | 46.20% | 35.20% | 24.09% |
| Operating Income | 318.21M | 4.87M | -83.30M | -217.88M | 171.46M | 421.45M | 440.86M | 263.38M | 364.73M | 266.37M | 345.44M | 227.95M | 183.15M | 144.10M | 87.47M | 45.11M | 3.52M | -37.12M |
| Operating Income Ratio | 31.38% | 0.59% | -8.97% | -33.26% | 14.56% | 36.90% | 39.95% | 27.40% | 41.57% | 34.33% | 47.46% | 38.28% | 38.54% | 42.02% | 35.67% | 28.30% | 3.80% | -107.42% |
| Total Other Income/Expenses | -7.58M | -7.99M | -9.76M | -79.33M | -30.60M | -10.12M | -8.20M | 45.11M | 50.00M | -20.58M | 77.36M | 60.96M | 39.00M | 28.78M | 19.30M | 14.29M | 13.82M | 5.61M |
| Income Before Tax | 310.63M | 28.96M | -53.39M | -282.41M | 229.23M | 411.34M | 432.66M | 308.49M | 236.95M | 245.80M | 347.96M | 288.91M | 222.16M | 172.88M | 106.77M | 59.40M | 18.87M | -31.51M |
| Income Before Tax Ratio | 30.63% | 3.51% | -5.75% | -43.11% | 19.47% | 36.01% | 39.21% | 32.09% | 27.01% | 31.68% | 47.81% | 48.51% | 46.75% | 50.41% | 43.53% | 37.27% | 20.40% | -91.17% |
| Income Tax Expense | 27.27M | -16.48M | -51.69M | -46.59M | 19.19M | 53.37M | 67.27M | 51.83M | 29.95M | 32.38M | 49.63M | 30.78M | 25.09M | 16.37M | -3.54M | -3.04M | 3.83M | 1.29M |
| Net Income | 294.61M | 49.30M | -1.70M | -235.81M | 229.30M | 369.66M | 388.72M | 268.10M | 210.70M | 212.41M | 295.26M | 256.84M | 196.30M | 156.51M | 110.31M | 62.44M | 18.87M | -31.51M |
| Net Income Ratio | 29.05% | 5.97% | -0.18% | -36.00% | 19.47% | 32.36% | 35.23% | 27.89% | 24.02% | 27.38% | 40.57% | 43.13% | 41.31% | 45.64% | 44.98% | 39.17% | 20.40% | -91.17% |
| EPS | 0.48 | 0.08 | 0.00 | -0.38 | 0.37 | 0.72 | 0.76 | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.38 | 0.33 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.48 | 0.08 | 0.00 | -0.38 | 0.37 | 0.72 | 0.76 | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.38 | 0.33 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 613.78M | 616.79M | 616.21M | 616.21M | 616.21M | 513.42M | 511.47M | 505.85M | 0.00 | 0.00 | 0.00 | 0.00 | 516.57M | 474.28M | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 613.78M | 616.79M | 616.21M | 616.21M | 616.21M | 513.42M | 511.47M | 505.85M | 0.00 | 0.00 | 0.00 | 0.00 | 516.57M | 474.28M | 0.00 | 0.00 | 0.00 | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports